MP
LVAC

Mangrove Partners’s LAVA Medtech Acquisition Corp. Class A Common Stock LVAC Stock Holding History

Mangrove Partners’s Portfolio LVAC Stock Details LVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400,000
Closed -$3.98M – 539
2022
Q2 		$3.98M Buy
+400,000
New +$3.99M 0.2% 218

Other funds holding LVAC

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Mangrove Partners's LVAC Position: Q3 2022 in Review

Mangrove Partners sold out of LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) in Q3 2022, closing a stake of 400,000 shares — an estimated $3.98M sold.

Mangrove Partners first reported a position in LVAC in Q2 2022 and held it in 1 quarter. The position peaked at $3.98M in Q2 2022. 49 funds tracked by Wall St. Rank hold LVAC as of Q3 2022.

  • Mangrove Partners reported no remaining LAVA Medtech Acquisition Corp. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 400,000 LAVA Medtech Acquisition Corp. Class A Common Stock shares in Q3 2022, an estimated $3.98M.
  • Mangrove Partners first reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock in Q2 2022 and held it in 1 quarter.
  • Mangrove Partners's LAVA Medtech Acquisition Corp. Class A Common Stock position peaked at $3.98M in Q2 2022.
  • 49 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Class A Common Stock as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.